Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Histopathology. 2018 Oct;73(4):634-644. doi: 10.1111/his.13666. Epub 2018 Jul 5.
Infantile fibrosarcoma is characterised by intersecting fascicles of spindle cells and ETV6-NTRK3 gene fusion in most cases. Given histological overlap with other spindle-cell tumours, the diagnosis can be challenging and often requires molecular confirmation. A recently developed pan-TRK antibody shows promise for identifying tumours with NTRK fusions. The purpose of this study was to evaluate the potential diagnostic utility of pan-TRK immunohistochemistry for infantile fibrosarcoma.
We evaluated whole-tissue sections from 210 cases, including 15 infantile fibrosarcomas; five each lipofibromatosis-like neural tumour and lipofibromatosis; 10 each primitive myxoid mesenchymal tumour of infancy (PMMTI) and low-grade myofibroblastic sarcoma; 15 each fibrous hamartoma of infancy (FHI), myofibroma/myofibromatosis and desmoid-type fibromatosis; and 20 each low-grade fibromyxoid sarcoma, synovial sarcoma, spindle-cell rhabdomyosarcoma, malignant peripheral nerve sheath tumour, fibrosarcomatous dermatofibrosarcoma protuberans (F-DFSP) and nodular fasciitis. Immunohistochemistry was performed using a rabbit monoclonal pan-TRK antibody. Immunoreactivity for pan-TRK was observed in all 15 (100%) infantile fibrosarcomas, including diffuse immunoreactivity (>50% of cells) in 14 (93%) cases. Pan-TRK was positive in all five (100%) lipofibromatosis-like neural tumours. Of the 190 histological mimics, diffuse pan-TRK immunoreactivity was noted in 16 (8%) cases, including five PMMTI, five FHI (highlighting predominantly the primitive myxoid spindle-cell components), three F-DFSP, one low-grade myofibroblastic sarcoma, one myofibroma and one spindle-cell rhabdomyosarcoma.
Diffuse pan-TRK immunoreactivity is a highly sensitive but not entirely specific diagnostic marker for infantile fibrosarcoma, and may be helpful in selecting patients for TRK-targeted therapy. As expected, lipofibromatosis-like neural tumours, which harbour NTRK1 fusions, also show diffuse pan-TRK immunoreactivity.
婴儿纤维肉瘤的特征是大多数情况下存在交织的梭形细胞束和 ETV6-NTRK3 基因融合。鉴于与其他梭形细胞肿瘤的组织学重叠,诊断具有挑战性,通常需要分子确认。最近开发的泛 TRK 抗体显示出识别具有 NTRK 融合的肿瘤的潜力。本研究旨在评估泛 TRK 免疫组化在婴儿纤维肉瘤中的潜在诊断效用。
我们评估了 210 例病例的全组织切片,包括 15 例婴儿纤维肉瘤;脂肪纤维瘤病样神经肿瘤和脂肪纤维瘤病各 5 例;婴儿原始黏液性间叶瘤和低级肌纤维母细胞瘤各 10 例;婴儿纤维性错构瘤、肌纤维瘤/肌纤维母细胞瘤和韧带样纤维瘤病各 15 例;低级纤维黏液瘤、滑膜肉瘤、梭形细胞横纹肌肉瘤、恶性外周神经鞘肿瘤、纤维肉瘤性隆突性皮肤纤维肉瘤(F-DFSP)和结节性筋膜炎各 20 例。使用兔单克隆泛 TRK 抗体进行免疫组织化学染色。所有 15 例(100%)婴儿纤维肉瘤均观察到泛 TRK 免疫反应,包括 14 例(93%)弥漫性免疫反应(>50%的细胞)。所有 5 例(100%)脂肪纤维瘤病样神经肿瘤均为阳性。在 190 例组织学模拟物中,16 例(8%)出现弥漫性泛 TRK 免疫反应,包括 5 例婴儿原始黏液性间叶瘤、5 例婴儿纤维性错构瘤(主要突出原始黏液性梭形细胞成分)、3 例 F-DFSP、1 例低级肌纤维母细胞瘤、1 例肌纤维瘤和 1 例梭形细胞横纹肌肉瘤。
弥漫性泛 TRK 免疫反应是婴儿纤维肉瘤高度敏感但非完全特异的诊断标志物,可能有助于选择接受 TRK 靶向治疗的患者。如预期的那样,携带 NTRK1 融合的脂肪纤维瘤病样神经肿瘤也显示弥漫性泛 TRK 免疫反应。